← Back to Search

Antibiotic

Magnetic Resonance-Positron Emission Tomography Imaging for Back Pain (IGNITE Trial)

Phase 2
Waitlist Available
Led By Marco L Loggia, PhD
Research Sponsored by Marco Loggia
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Chronic or sub-acute low back pain
on a stable pain treatment
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 weeks
Awards & highlights

IGNITE Trial Summary

This trial will study whether minocycline can help treat low back pain by reducing neuroinflammation in the brain and spine.

Who is the study for?
This trial is for English-speaking individuals who can consent to participate, have chronic or sub-acute low back pain, and are on a stable pain treatment regimen. It's not specified who cannot join the trial.Check my eligibility
What is being tested?
The study is testing if minocycline hydrochloride can reduce neuroinflammation and alleviate symptoms in patients with low back pain, using brain imaging techniques alongside a placebo comparison.See study design
What are the potential side effects?
Minocycline may cause side effects like dizziness, fatigue, gastrointestinal issues, skin reactions, and possibly affect liver enzymes. The exact side effects will vary among individuals.

IGNITE Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have had lower back pain for a long time.
Select...
My pain management treatment has not changed recently.
Select...
I have had lower back pain for a long time.

IGNITE Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Changes in brain PET signal
Secondary outcome measures
Changes in pain outcomes as measured by self report on a 0-100 numerical pain rating scale
Changes in spinal PET signal

Side effects data

From 2017 Phase 2 trial • 22 Patients • NCT01746043
20%
Peripheral Neuropathy
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo
Armodafinil+Minocycline
Minocycline
Armodafinil

IGNITE Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Minocycline ArmExperimental Treatment2 Interventions
Evaluation with Magnetic Resonance-Positron Emission Tomography Imaging and/or behavioral pain assessment before and after a 2-week trial of Minocycline Hydrochloride, 100mg capsule
Group II: Placebo ArmPlacebo Group2 Interventions
Evaluation with Magnetic Resonance-Positron Emission Tomography Imaging and/or behavioral pain assessment before and after 2 weeks of treatment with a placebo capsule.

Find a Location

Who is running the clinical trial?

Marco LoggiaLead Sponsor
National Institute of Neurological Disorders and Stroke (NINDS)NIH
1,335 Previous Clinical Trials
648,442 Total Patients Enrolled
3 Trials studying Back Pain
416 Patients Enrolled for Back Pain
Marco L Loggia, PhDPrincipal InvestigatorMassachusetts General Hospital

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~1 spots leftby Apr 2024